Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age
暂无分享,去创建一个
E. Alexeeva | A. Alshevskaya | T. Sleptsova | R. Denisova | A. Moskalev | K. Isaeva | T. Dvoryakovskaya | Alexandra Chomahidze | A. Fetisova | A. Mamutova | Tatyana Sleptsova